---
title: "CORT.US (CORT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CORT.US/news.md"
symbol: "CORT.US"
name: "CORT.US"
parent: "https://longbridge.com/en/quote/CORT.US.md"
datetime: "2026-05-20T15:18:11.287Z"
locales:
  - [en](https://longbridge.com/en/quote/CORT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CORT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CORT.US/news.md)
---

# CORT.US (CORT.US) — Related News

### [Does Corcept Therapeutics' (CORT) UBS Upgrade and Insider Gifting Reframe Its Oncology Ambitions?](https://longbridge.com/en/news/286679819.md)
*2026-05-17T18:07:12.000Z*
> UBS Group upgraded Corcept Therapeutics, citing increased confidence in its ovarian cancer therapy, Lifyoril. This upgra

### [12:30 ETCorti steps up its support for the next wave of healthcare startups as OpenAI pushes into the space and others retreat from Europe](https://longbridge.com/en/news/286293087.md)
*2026-05-13T16:30:39.000Z*
> Corti has launched its Startup Acceleration Program to support healthcare AI startups in overcoming regulatory barriers,

### [Corcept Therapeutics (NASDAQ:CORT) Upgraded by Zacks Research to Hold Rating](https://longbridge.com/en/news/285355774.md)
*2026-05-06T10:25:58.000Z*
> Zacks Research upgraded Corcept Therapeutics (NASDAQ:CORT) from a "strong sell" to a "hold" rating. Other analysts have 

### [Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Volatility In The Share Price](https://longbridge.com/en/news/284944974.md)
*2026-05-01T22:05:32.000Z*
> Corcept Therapeutics (CORT) is currently priced at approximately $51.42, following significant volatility in its share p

### [](https://longbridge.com/en/news/284926398.md)
*2026-05-01T17:31:45.000Z*
> Corcept Therapeutics shares are trading higher after the company announced results from its phase 2 DAZALS trial of dazu

### [Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk](https://longbridge.com/en/news/284913094.md)
*2026-05-01T14:52:10.000Z*
> Corcept Therapeutics shares rose after the Phase 2 DAZALS study showed an 87% reduction in death risk for ALS patients t

### [Corcept Earnings: What To Look For From CORT](https://longbridge.com/en/news/284485351.md)
*2026-04-29T03:13:31.000Z*
> Corcept Therapeutics will announce its earnings results this Thursday after market hours. Last quarter, the company miss

### [Corcept Therapeutics (CORT) Projected to Post Earnings on Thursday](https://longbridge.com/en/news/284102139.md)
*2026-04-26T07:17:18.000Z*
> Corcept Therapeutics (NASDAQ:CORT) is set to release its Q1 2026 earnings on April 30, with analysts predicting a loss o